Headquartered in Frederick, MD Fiscal year ends December NASDAQ: RNAC cartesiantherapeutics.com
Cartesian Therapeutics is a late clinical-stage biotechnology company developing cell therapies for autoimmune diseases. Its lead asset, Descartes-08, is an autologous chimeric antigen receptor T-cell therapy (CAR-T) targeting B cell maturation antigen (BCMA).
Unlike conventional DNA-based CAR-T therapies, Descartes-08 is designed to be given as outpatient infusions without preconditioning chemotherapy. It also avoids the risk of genomic integration.
Descartes-08 is in development across three programs:
- Phase 3 (AURORA) for generalized myasthenia gravis, with data expected in 1Q27 and a BLA planned for mid-2027.
- Phase 2 (TRITON) for myositis, specifically dermatomyositis and antisynthetase syndrome.
- Phase 1/2 (HELIOS) for pediatric autoimmune diseases, including juvenile dermatomyositis.
The candidate holds FDA Orphan Drug and Regenerative Medicine Advanced Therapy designations in MG and Rare Pediatric Disease Designation in JDM.
The company is also developing in vivo CAR-T approaches through a partnership with WestGene BioPharma using targeted lipid nanoparticles. It is building medical affairs and commercial capabilities ahead of a potential launch.
Cartesian currently has no product revenue and has historically recorded grant and collaboration revenue. It funds operations through cash reserves, a K2 HealthVentures credit facility and an at-the-market equity program. Updated
A single analyst note sent Kyverna Therapeutics tumbling despite a clinical milestone that had investors cheering just weeks ago, and the question now is whether the selloff marks a buying opportunity or…
Cartesian Therapeutics is a late clinical-stage biotechnology company developing cell therapies for autoimmune diseases. Its lead asset, Descartes-08, is an autologous chimeric antigen receptor T-cell therapy (CAR-T) targeting B cell maturation antigen (BCMA).
The Wall Street consensus 12-month price target for RNAC is $33.67.
